BioSpace News Archive

POINT Biopharma Inc. and TerraPower announced they signed a research and clinical supply agreement for the medical radioisotope actinium-225, further expanding the number of radioisotopes in POINT’s pipeline of next-generation precision radiopharmaceutical treatments.

Plus Therapeutics, Inc. (Nasdaq: PSTV ) (the “Company”), a clinical-stage pharmaceutical company developing novel, targeted therapies for rare and difficult to treat cancers, today announced that it has entered into a master services agreement (MSA) with Piramal Pharma Solutions (PPS) for the development, manufacture, and supply of Plus’ Rhenium NanoLiposome (RNL™) intermediate drug product.

JCR Pharmaceuticals Announces Approval of IZCARGO ® (Pabinafusp Alfa) for Treatment of MPS II (Hunter Syndrome) in Japan - First Approved Enzyme Replacement Therapy for MPS II to Penetrate Blood-Brain Barrier via Intravenous Administration, Validating JCR’s J-Brain Cargo ® Technology -

Creative Medical Technology Holdings, Inc. (OTC: CELZ), a leading commercial stage biotechnology company focused on a regenerative approach to Immunotherapy, Urology, Neurology and Orthopedics, today announced its intent to launch Virtual Physician™ focused on telehealth solutions for regenerative medicine this summer.

Lantern Pharma Inc. (NASDAQ: LTRN), will present new data on LP-184, a next-generation, targeted small molecule in the acylfulvene drug class, showcasing its potency across various 2D and 3D models of prostate cancer, at the American Association for Cancer Research (AACR) Virtual Annual Meeting, taking place from April 10-15, 2021.

Hygieia, a digital health company for insulin therapy management, has appointed Ted Bucknam as president. Bucknam will spearhead the company’s clinical expansion, working with endocrinologists, referring physicians and clinic partners throughout Michigan and the U.S.

Akero Therapeutics, Inc. (Nasdaq: AKRO), a cardio-metabolic biotechnology company developing transformational treatments for non-alcoholic steatohepatitis (NASH), today announced the first patient has been randomized for dosing in its Phase 2b clinical study of Efruxifermin (EFX) in the treatment of patients with F2/F3 NASH (the HARMONY study).

Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, announced today its full year 2020 financial results and provided a business update.

Lyell Immunopharma, Inc. (Lyell), an immuno-oncology company dedicated to the mastery of T cells to cure solid tumors, today announced the completion of its $65 million LyFE Manufacturing Center in Bothell, Washington.

Cano Health (the “Company”), a leading value-based primary care delivery platform for seniors, today announced the appointment of Brian Koppy as Chief Financial Officer, effective April 5, 2021.